Memantine, a long-approved and cost-effective drug used to treat Alzheimer's disease, could also benefit patients with sickle ...
Memantine, a long-approved and cost-effective drug used to treat Alzheimer’s disease, could also benefit patients with sickle ...
MedPage Today on MSN
Autoimmune Anemia Is the Latest Condition Found Responsive to CAR-T Therapy
Eleven patients with refractory autoimmune hemolytic anemia (AIHA) were all brought into drug-free remission with CAR T-cell ...
Mitapivat is the first FDA-approved oral therapy for anaemia in all forms of thalassemia Reduced transfusion dependence may ...
The American Red Cross is calling for more blood donations from people who are African American, Black or multiracial, saying those donations are critical to treating patients with sickle cell disease ...
10don MSN
FDA approves first oral drug for thalassemia anemia, offering new hope beyond blood transfusions
The US FDA has approved the drug Mitapivat, marketed as Aqvesme, as the very first oral therapy for anemia in adults with ...
When someone gives blood, the donation is usually separated into components to use for specific needs. But in some cases, a ...
Virginia sickle cell advocates prepare legislative push as Del. Candi Mundon King continues fight months after losing ...
SouthCoastToday.com on MSN
Critical winter blood shortage looming. Donate at these SouthCoast drives
With a winter blood shortage looming, donate blood for a chance to win Super Bowl tickets. Here’s where to donate in Greater ...
HUTCHMED reported positive Phase 3 trial results for sovleplenib in autoimmune anemia, supporting a planned China drug filing ...
Suleika Jaouad's leukemia experience highlights the importance of mindfulness and support networks in managing the disease.
India Today on MSN
US approves first pill for thalassemia anemia: What this means for India
The US FDA has approved mitapivat, the first oral medicine for treating anemia caused by thalassemia. At present, mitapivat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results